Prediction of response in non-small cell lung cancers treated with EGFR1 tyrosine kinase inhibitors;Predikce účinnosti tyrozinkinázových inhibitorů EGFR1 v léčbě nemalobuněč ných plicních karcinomů

Klinicka Onkologie

Volumn 19, Issue 3, 2006, Pages 171-176

  Berkovcova J ^a   Hajduch M ^a   Dziechciarkova M ^a   Trojanec, R ^a   Janostakova A ^a   Wiecek, S ^a   Grygarkova I ^a   Kolek, V ^a   Vorlicek J ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Egfr1; Erlotinib; Gefitinib; k ras; Non small cell lung cancer; Point mutations; Tyrosine kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN;

CANCER CHEMOTHERAPY; CANCER MORTALITY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; LUNG NON SMALL CELL CANCER; PREDICTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

EID: 33751079351     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Baselg J.: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer 2001; 37, Suppl 4: 16-22.
2. Pao W., Miller V.: Epidermal growth factor receptor mutations, Small-molecule kinase inhibitors, and Non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol, 2005; 23: 2556-2568.
3. Grandis JR., Sok JC.: Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102: 37-46.
4. Roskoski R.: The ErbB/Her receptor protein-tyrosine kinase and cancer. Biochem Biophys Res Commun 2004; 319: 1155-1164.
5. Grandis JR., Zeng O., Tweardy DJ.: Retinoic acid normalizes the increased gene transcriptiono rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 1996; 2: 237-240.
6. Trojanec R., Špačková K., Cwiertka K. et al.: Amplifikace genu Her-2/neu: molekulární, buněč né a klinické aspekty. Klin Farmakol Farmac 2002; 16: 23-29.
7. Lynch TJ., Bell DW., Sordella R. et al.: Activating mutations' in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004; 350: 2129-2139.
8. Shigematsu H., Lin L., Takahashi T. et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005; 97: 339-328.
9. Kosaka T., Yatabe Y., Endoh H. et al.: Mutation of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res, 2004; 64: 8919-8923.
10. Yang SH., Mechanic LE., Yant P. et al.: Mutations in th tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 2005; 11: 2106-2110.
11. Prigent SA., Nagane M., Mishima K. et al.: Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras- Shc-Grb2 pathway. J Biol Chem 1996; 271: 25639-25645.
12. Sato JD., Kawamoto T., Le AD. et al.: Biological effects in vitro of monoclonal antibodies tu human epidermal growth factor receptors. Mol Biol Med 1983; 1: 511-529.
13. Alekshun T., Garrett Ch.: Targeted therapies in the treatment of colorectal cancers. Cancer Control 2005; 12: 105-110.
14. Pao W., Miller V., Zakowski M. et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitineb and erlotinib. PNAS 2004; 101: 13306-13311.
15. Arora A., Scholar EM.: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther, 2005; 315: 971-979.
16. Druker BJ., Lydon NB.: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia, J Clin Invest, 2000; 105: 3-7.
17. Gorre ME., Mohammed M., Ellwood K. et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001; 293: 876-880.
18. Burgess MR., Skaggs BJ., Shah NP., Lee FY., Sawyers CL.: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. PNAS, 2005; 102: 3395-3400.
19. Gumireddy K., Baker SJ., Cosenza SC. et al: A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. PNAS, 2005; 102: 1992-1997.
20. Kobayashi S., Boggon TJ., Dayaram T. et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005; 352: 786-792.
21. Shigematsu H., Takahashi T., Nomura M. et al.: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res, 2005; 65: 1642-1646.
22. Soung YH., Lee JW., Kim SY. et al.: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch, 2005; 446: 483-488.
23. Tsao MS., Sakurada A., Cutz JC. et al.: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med, 2005; 253: 133-144.